These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 22190064)

  • 1. Assessment of lopinavir pharmacokinetics with respect to developmental changes in infants and the impact on weight band-based dosing.
    Nikanjam M; Chadwick EG; Robbins B; Alvero C; Palumbo P; Yogev R; Pinto J; Hazra R; Hughes ML; Heckman BE; Capparelli EV;
    Clin Pharmacol Ther; 2012 Feb; 91(2):243-9. PubMed ID: 22190064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population Pharmacokinetics of Lopinavir/Ritonavir: Changes Across Formulations and Human Development From Infancy Through Adulthood.
    Yang J; Nikanjam M; Best BM; Pinto J; Chadwick EG; Daar ES; Havens PL; Rakhmanina N; Capparelli EV
    J Clin Pharmacol; 2018 Dec; 58(12):1604-1617. PubMed ID: 30252146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lopinavir/ritonavir plus lamivudine and abacavir or zidovudine dose ratios for paediatric fixed-dose combinations.
    Bouazza N; Foissac F; Fauchet F; Burger D; Kiechel JR; Treluyer JM; Capparelli EV; Lallemant M; Urien S
    Antivir Ther; 2015; 20(2):225-33. PubMed ID: 25279808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of pediatric lopinavir/ritonavir tablets in children when administered twice daily according to FDA weight bands.
    Bastiaans DE; Forcat S; Lyall H; Cressey TR; Hansudewechakul R; Kanjanavanit S; Noguera-Julian A; Königs C; Inshaw JR; Chalermpantmetagul S; Saïdi Y; Compagnucci A; Harper LM; Giaquinto C; Colbers AP; Burger DM;
    Pediatr Infect Dis J; 2014 Mar; 33(3):301-5. PubMed ID: 24356253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetics and dosing regimen optimisation of lopinavir in Chinese adults infected with HIV.
    Niu WJ; Sun T; Liu L; Liu XQ; Zhang RF; Yin L; Wang JR; Jia XF; Lu HZ; Zhong MK; Jiao Z; Zhang LJ
    Basic Clin Pharmacol Toxicol; 2019 Apr; 124(4):456-465. PubMed ID: 30346663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase II/III Trial of Lopinavir/Ritonavir Dosed According to the WHO Pediatric Weight Band Dosing Guidelines.
    Pinto JA; Capparelli EV; Warshaw M; Zimmer B; Cressey TR; Spector SA; Qin M; Smith B; Siberry GK; Mirochnick M;
    Pediatr Infect Dis J; 2018 Feb; 37(2):e29-e35. PubMed ID: 29088027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Model-Based Analysis of Unbound Lopinavir Pharmacokinetics in HIV-Infected Pregnant Women Supports Standard Dosing in the Third Trimester.
    Chen J; Malone S; Prince HM; Patterson KB; Dumond JB
    CPT Pharmacometrics Syst Pharmacol; 2016 Mar; 5(3):147-57. PubMed ID: 27069778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetics of lopinavir/ritonavir (Kaletra) in HIV-infected patients.
    López Aspiroz E; Santos Buelga D; Cabrera Figueroa S; López Galera RM; Ribera Pascuet E; Domínguez-Gil Hurlé A; García Sánchez MJ
    Ther Drug Monit; 2011 Oct; 33(5):573-82. PubMed ID: 21912331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Pharmacokinetics of Lopinavir/Ritonavir Oral Solution in Preterm and Term Infants Starting Before 3 Months of Age.
    Bekker A; Yang J; Wang J; Cotton MF; Cababasay M; Wiesner L; Moye J; Browning R; Nakwa FL; Rabie H; Violari A; Mirochnick M; Cressey TR; Capparelli EV
    Pediatr Infect Dis J; 2024 Apr; 43(4):355-360. PubMed ID: 38190642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concentration-response model of lopinavir/ritonavir in HIV-1-infected pediatric patients.
    Bouazza N; Urien S; Blanche S; Hirt D; Foissac F; Benaboud S; Tréluyer JM; Frange P
    Pediatr Infect Dis J; 2014 Aug; 33(8):e213-8. PubMed ID: 24509655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population Pharmacokinetics of Lopinavir in Severely Malnourished HIV-infected Children and the Effect on Treatment Outcomes.
    Archary M; Mcllleron H; Bobat R; La Russa P; Sibaya T; Wiesner L; Hennig S
    Pediatr Infect Dis J; 2018 Apr; 37(4):349-355. PubMed ID: 29227461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Côte d'Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial.
    Dahourou DL; Amorissani-Folquet M; Malateste K; Amani-Bosse C; Coulibaly M; Seguin-Devaux C; Toni T; Ouédraogo R; Blanche S; Yonaba C; Eboua F; Lepage P; Avit D; Ouédraogo S; Van de Perre P; N'Gbeche S; Kalmogho A; Salamon R; Meda N; Timité-Konan M; Leroy V;
    BMC Med; 2017 Apr; 15(1):85. PubMed ID: 28434406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early initiation of lopinavir/ritonavir in infants less than 6 weeks of age: pharmacokinetics and 24-week safety and efficacy.
    Chadwick EG; Pinto J; Yogev R; Alvero CG; Hughes MD; Palumbo P; Robbins B; Hazra R; Serchuck L; Heckman BE; Purdue L; Browning R; Luzuriaga K; Rodman J; Capparelli E;
    Pediatr Infect Dis J; 2009 Mar; 28(3):215-9. PubMed ID: 19209098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population Pharmacokinetics of Pediatric Lopinavir/Ritonavir Oral Pellets in Children Living with HIV in Africa.
    Chupradit S; Wamalwa DC; Maleche-Obimbo E; Kekitiinwa AR; Mwanga-Amumpaire J; Bukusi EA; Nyandiko WM; Mbuthia JK; Swanson A; ; Cressey TR; Punyawudho B; Musiime V;
    Clin Pharmacol Ther; 2024 May; 115(5):1105-1113. PubMed ID: 38247190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abacavir Exposure in Children Cotreated for Tuberculosis with Rifampin and Superboosted Lopinavir-Ritonavir.
    Rabie H; Tikiso T; Lee J; Fairlie L; Strehlau R; Bobat R; Liberty A; McIlleron H; Andrieux-Meyer I; Cotton M; Lallemant M; Denti P
    Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32071055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of lopinavir/ritonavir and efavirenz in food insecure HIV-infected pregnant and breastfeeding women in Tororo, Uganda.
    Bartelink IH; Savic RM; Mwesigwa J; Achan J; Clark T; Plenty A; Charlebois E; Kamya M; Young SL; Gandhi M; Havlir D; Cohan D; Aweeka F
    J Clin Pharmacol; 2014 Feb; 54(2):121-32. PubMed ID: 24038035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Confirming model-predicted pharmacokinetic interactions between bedaquiline and lopinavir/ritonavir or nevirapine in patients with HIV and drug-resistant tuberculosis.
    Brill MJ; Svensson EM; Pandie M; Maartens G; Karlsson MO
    Int J Antimicrob Agents; 2017 Feb; 49(2):212-217. PubMed ID: 28038962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pharmacokinetics of lopinavir/ritonavir when given with isoniazid in South African HIV-infected individuals.
    Decloedt EH; van der Walt JS; McIlleron H; Wiesner L; Maartens G
    Int J Tuberc Lung Dis; 2015 Oct; 19(10):1194-6. PubMed ID: 26459532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low dose lopinavir/ritonavir tablet achieves adequate pharmacokinetic parameters in HIV-infected Thai adolescents.
    Klinklom A; Puthanakit T; Gorowara M; Phasomsap C; Kerr S; Sriheara C; Ananworanich J; Burger D; Ruxrungtham K; Pancharoen C
    Antivir Ther; 2012; 17(2):283-9. PubMed ID: 22293065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lopinavir/ritonavir population pharmacokinetics in neonates and infants.
    Urien S; Firtion G; Anderson ST; Hirt D; Solas C; Peytavin G; Faye A; Thuret I; Leprevost M; Giraud C; Lyall H; Khoo S; Blanche S; Tréluyer JM
    Br J Clin Pharmacol; 2011 Jun; 71(6):956-60. PubMed ID: 21564164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.